The ZUMA-1 & ZUMA-7 phase 1, 2 & 3 trials aimed to investigate the real-world axi-cel manufacturing experience and product characteristics in patients with R/R LBCL. Researchers noticed that earlier axi-cel treatment in R/R LBCL enhances manufacturing success and product quality. Axicabtagene ciloleucel (axi-cel), an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, […]...
EHA 2024
Coverage of Annual Congress of the European Hematology Association
Jun 13
-Jun 16, 2024